NEW YORK, May 16 (GenomeWeb News) - Agilent Technologies yesterday reported 8-percent quarterly revenue growth for its Bio-Analytical Measurement segment amid an overall revenue increase of 12 percent.
For the company's second fiscal quarter ended April 30, orders in the BioAnalytical segment rose 4 percent to $401 million from $385 million in the same period of 2005.
Life sciences orders were up 4 percent, "with demand from traditional pharmaceutical customers down in the
Demand for proteomics and genomics products was up more than 20 percent from last year, the company said.
Revenues for the Bio-Analytical segment increased 8 percent to $372 million from $344 million in the second quarter of 2005.
Agilent's total orders increased 21 percent to $1.59 billion from $1.32 billion, while total revenues rose 12 percent to $1.43 billion from $1.28 billion in the prior-year period.
The company's total R&D spending rose 4 percent to $197 million from $189 million in the comparable period of 2005.
Agilent's net income increased 21 percent to $115 million from $95 million.
The company held $2.7 billion in cash and cash equivalents as of April 30.